AR and metastatic prostate carcinoma: Interfering with production of male hormones that activate the androgen receptor (AR), a nuclear hormone receptor that promotes proliferation and luminal differentiation, and interfering with binding of androgens to the AR are the principal treatment strategies for metastatic prostate cancer (2).